



Drug Name: Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone, Tradjenta, Jentadueto, Jentadueto XR, Januvia, Janumet, Janumet XR
Revision Dates: 05-2012, 05-2015, 09-2017, 7/2018
Totally Revised Date: 09-2017-2018

Drug Name:	<u>Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone, Tradjenta, Jentadueto, Jentadueto XR, Januvia, Janumet, Janumet XR</u> Alogliptin-metformin, Alogliptin-pioglitazone
Required Medical Information:	<ul style="list-style-type: none"> • If patient's most recent Hgb A1c is less than 10%: <ul style="list-style-type: none"> ○ Patient is diagnosed with Type 2 Diabetes Mellitus (T2DM); and ○ Patient has failed a recent trial with an adequate or maximized dose and appropriate duration of metformin (at least 2 grams/day); and ○ Patient has failed at least one other generic antihyperglycemic medication (e.g. sulfonylurea product). • If patient's most recent Hgb A1c is equal to or greater than 10%: <ul style="list-style-type: none"> ○ Patient has failed an adequate dose and duration of basal insulin therapy.
Renewal Criteria:	<ul style="list-style-type: none"> • Documented improvement in Hgb A1c since initiating therapy with the requested drug. <u>A1c in the past 30 days showing clinical improvement</u>
Note(s):	<ul style="list-style-type: none"> • All requests must be accompanied by an Hgb A1c lab result within 3 months from the date of receipt. • All requests are reviewed for member adherence to current diabetes medications.
Coverage Duration:	<ul style="list-style-type: none"> • <u>Initial:</u> 4 months • <u>Continuation of therapy:</u> • <u>A1c improvement $\geq 0.5\%$ then approve for 3 years</u> • <u>A1c improvement between 0.2%-0.5% then approve 4 months</u> • <u>3 years</u> <u>Need to have improvement of at least 0.2% to be approved upon continuation</u>

Commented [LM1]: Will no longer be asking for documentation in order for it to be ePA compatible. Criteria will now read:
 - A1c in the past 30 days showing clinical improvement
 *Need to have improvement of at least 0.2% to be approved upon continuation

Formatted: Normal, No bullets or numbering

Formatted: Font: Garamond, 12 pt, Bold

Formatted: List Paragraph, Bulleted + Level: 1 + Aligned at: 0" + Indent at: 0.25"

Formatted: Font: Garamond, 12 pt

Formatted: Font: Calibri, 11 pt

Formatted: Font color: Auto

Formatted: Font: Garamond, 12 pt, Font color: Auto

Commented [LM2]: Dependent on response, see above

Formatted: Font color: Auto